The long-term goal of this project is to elucidate the role of histone deacetylase 6 (HDAC6) in platinum resistance of non-small cell lung cancer (NSCLC). There are about 220,000 new lung cancer patients in the US annually which makes lung cancer the leading cause of cancer-related mortality in both men and women. Two first line regimens of lung cancer treatment are platinum with taxane and platinum with gemcitabine. One of the major obstacles of these treatments is that patients often develop resistance to platinum. HDACs are enzymes which remove acetyl moiety from histone and non-histone proteins, thereby being involved in a wide variety of biological processes including transcription regulation, cell growth/differentiation, apoptosis, etc. HDAC inhibitors now hold great promises in lung cancer treatment partly in that they are able to restore chemosensitivity. However, the mechanisms by which HDAC inhibitors enhance chemosensitivity are largely unknown. Our preliminary data has shown that one of the HDACs, termed HDAC6, acts as both a deacetylase and a ubiquitin E3 ligase to promote a key DNA mismatch repair (MMR) protein MSH2 deacetylation, polyubiquitination and degradation. Our results also indicate that deacetylation of MSH2 down-regulates MSH2 MMR activity. Moreover, we have shown that HDAC6 protein levels positively correlate with cisplatin resistance in a panel of 15 NSCLC cell lines. Given the fact that MSH2 serves as a sensor for cisplatin-induced DNA adducts and loss of MSH2 causes cisplatin resistance, we hypothesize that down-regulation of MSH2 protein level and its MMR activity governed by HDAC6-mediated deacetylation and ubiquitination contributes to platinum resistance. Therefore, in this proposal, we will first characterize HDAC6 ubiquitin E3 ligase activity towards MSH2 degradation and investigate how HDAC6-mediated deacetylation of MSH2 affects its MMR activity. We will then validate the role of HDAC6 in cisplatin resistance in a mouse xenograft model as well as in NSCLC patients'tissue specimens. The results of our research will identify HDAC6 as a novel therapeutic target in lung cancer treatment and show that HDAC6 and MSH2 may serve as biomarkers for platinum resistance in NSCLC patients. Our results will suggest the application of clinically relevant HDAC6-selective inhibitors which suppress HDAC6 deacetylase and E3 ligase activity for the treatment of NSCLC.
The proposed research has relevance to public health and NCI's mission. Chemo-resistance is the major challenge facing cancer treatment since many cancer patients relapse after a period of chemotherapy. Although, the pan histone deacetylase (HDAC) inhibitors used in clinical trials have shown promises to restore chemo-sensitivity, they suppress numerous HDACs (HDAC1-11) of which may not all be involved in chemo-resistance. Our study, for the first time, has linked a specific HDAC, HDAC6, to chemo-resistance and suggested that HDAC6-selective inhibitors which suppress HDAC6 deacetylase and E3 ligase activity will achieve higher efficacy to restore the chemo-sensitivity than that of pan HDAC inhibitors. Once the role of HDAC6 in chemo-resistance has been established, the treating oncologists will screen cancer patients'tissue specimens for levels of HDAC6 and tailor chemotherapy accordingly.
|Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993|
|Quarni, Waise; Lungchukiet, Panida; Tse, Anfernee et al. (2017) RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression. J Steroid Biochem Mol Biol 173:157-167|
|Zhang, Mu; Hu, Chen; Tong, Dan et al. (2016) Ubiquitin-specific Peptidase 10 (USP10) Deubiquitinates and Stabilizes MutS Homolog 2 (MSH2) to Regulate Cellular Sensitivity to DNA Damage. J Biol Chem 291:10783-91|
|Haakenson, Joshua; Wu, Jheng-Yu; Xiang, Shengyan et al. (2015) HDAC6-Dependent Functions in Tumor Cells: Crossroad with the MAPK Pathways. Crit Rev Oncog 20:65-81|
|Lungchukiet, Panida; Sun, Yuefeng; Kasiappan, Ravi et al. (2015) Suppression of epithelial ovarian cancer invasion into the omentum by 1?,25-dihydroxyvitamin D3 and its receptor. J Steroid Biochem Mol Biol 148:138-47|
|Nelson, Nadine; Xiang, Shengyan; Zhang, Xiaohong et al. (2015) Murine pancreatic adenocarcinoma reduces Ikaros expression and disrupts T cell homeostasis. PLoS One 10:e0115546|
|Sun, Yuefeng; Sun, Jianwei; Lungchukiet, Panida et al. (2015) Fe65 Suppresses Breast Cancer Cell Migration and Invasion through Tip60 Mediated Cortactin Acetylation. Sci Rep 5:11529|
|Kasiappan, Ravi; Sun, Yuefeng; Lungchukiet, Panida et al. (2014) Vitamin D suppresses leptin stimulation of cancer growth through microRNA. Cancer Res 74:6194-204|
|Zhang, Mu; Xiang, Shengyan; Joo, Heui-Yun et al. (2014) HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutS?. Mol Cell 55:31-46|
|Haakenson, Joshua; Zhang, Xiaohong (2013) HDAC6 and ovarian cancer. Int J Mol Sci 14:9514-35|
Showing the most recent 10 out of 12 publications